ICD-10-PCS Codes

• 1 XW03306 (INTRODUCTION OF BREXANOLONE INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 2 XW03308 (INTRODUCTION OF SPESOLIMAB MONOCLONAL ANTIBODY INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 8)

• 3 XW03321 (INTRODUCTION OF CEFTAZIDIME-AVIBACTAM ANTI-INFECTIVE INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 1)

• 4 XW03326 (INTRODUCTION OF NERINITIDE INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 5 XW03331 (INTRODUCTION OF IDARUCIZUMAB, DABIGATRAN REVERSAL AGENT INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 1)

• 6 XW03336 (INTRODUCTION OF DURVALUMAB ANTINEOPLASTIC INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 7 XW0333A (INTRODUCTION OF BENTRACIMAB, TICAGRELOR REVERSAL AGENT INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 10)

• 8 XW03341 (INTRODUCTION OF ISAVUCONAZOLE ANTI-INFECTIVE INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 1)

• 9 XW0334A (INTRODUCTION OF CEFEPIME-TANIBORBACTAM ANTI-INFECTIVE INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 10)

• 10 XW03351 (INTRODUCTION OF BLINATUMOMAB ANTINEOPLASTIC IMMUNOTHERAPY INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 1)

• 11 XW03357 (INTRODUCTION OF NARSOPLIMAB MONOCLONAL ANTIBODY INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 12 XW03358 (INTRODUCTION OF MOSUNETUZUMAB ANTINEOPLASTIC INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 8)

• 13 XW0335A (INTRODUCTION OF CEFTOBIPROLE MEDOCARIL ANTI-INFECTIVE INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 10)

• 14 XW03366 (INTRODUCTION OF LEFAMULIN ANTI-INFECTIVE INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 15 XW03367 (INTRODUCTION OF TERLIPRESSIN INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 16 XW03368 (INTRODUCTION OF AFAMITRESGENE AUTOLEUCEL IMMUNOTHERAPY INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 8)

• 17 XW03372 (INTRODUCTION OF INACTIVATED COAGULATION FACTOR XA INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 2)

• 18 XW03377 (INTRODUCTION OF TRILACICLIB INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 19 XW03378 (INTRODUCTION OF TABELECLEUCEL IMMUNOTHERAPY INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 8)

• 20 XW03387 (INTRODUCTION OF LURBINECTEDIN INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 21 XW03388 (INTRODUCTION OF TREOSULFAN INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 8)

• 22 XW0338A (INTRODUCTION OF OBECABTAGENE AUTOLEUCEL INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 10)

• 23 XW03392 (INTRODUCTION OF DEFIBROTIDE SODIUM ANTICOAGULANT INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 2)

• 24 XW03396 (INTRODUCTION OF CEFTOLOZANE/TAZOBACTAM ANTI-INFECTIVE INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 25 XW03398 (INTRODUCTION OF INEBILIZUMAB-CDON INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 8)

• 26 XW0339A (INTRODUCTION OF ODRONEXTAMAB ANTINEOPLASTIC INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 10)

• 27 XW033A3 (INTRODUCTION OF BEZLOTOXUMAB MONOCLONAL ANTIBODY INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 3)

• 28 XW033A6 (INTRODUCTION OF CEFIDEROCOL ANTI-INFECTIVE INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 29 XW033A7 (INTRODUCTION OF CILTACABTAGENE AUTOLEUCEL INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 30 XW033B3 (INTRODUCTION OF CYTARABINE AND DAUNORUBICIN LIPOSOME ANTINEOPLASTIC INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 3)

• 31 XW033B6 (INTRODUCTION OF OMADACYCLINE ANTI-INFECTIVE INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 32 XW033B7 (INTRODUCTION OF AMIVANTAMAB MONOCLONAL ANTIBODY INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 33 XW033BA (INTRODUCTION OF ORCA-T ALLOGENEIC T-CELL IMMUNOTHERAPY INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 10)

• 34 XW033C3 (INTRODUCTION OF ENGINEERED AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR T-CELL IMMUNOTHERAPY INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 3)

• 35 XW033C6 (INTRODUCTION OF ECULIZUMAB INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 36 XW033C7 (INTRODUCTION OF AUTOLOGOUS ENGINEERED CHIMERIC ANTIGEN RECEPTOR T-CELL IMMUNOTHERAPY INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 37 XW033CA (INTRODUCTION OF ZANIDATAMAB ANTINEOPLASTIC INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 10)

• 38 XW033D6 (INTRODUCTION OF ATEZOLIZUMAB ANTINEOPLASTIC INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 39 XW033DA (INTRODUCTION OF DONISLECEL-JUJN ALLOGENEIC PANCREATIC ISLET CELLULAR SUSPENSION INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 10)

• 40 XW033E5 (INTRODUCTION OF REMDESIVIR ANTI-INFECTIVE INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 5)

• 41 XW033E6 (INTRODUCTION OF ETESEVIMAB MONOCLONAL ANTIBODY INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 42 XW033F3 (INTRODUCTION OF OTHER NEW TECHNOLOGY THERAPEUTIC SUBSTANCE INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 3)

• 43 XW033F5 (INTRODUCTION OF OTHER NEW TECHNOLOGY THERAPEUTIC SUBSTANCE INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 5)

• 44 XW033F6 (INTRODUCTION OF BAMLANIVIMAB MONOCLONAL ANTIBODY INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 45 XW033FA (INTRODUCTION OF NON-CHIMERIC ANTIGEN RECEPTOR T-CELL IMMUNE EFFECTOR CELL THERAPY INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 10)

• 46 XW033FB (INTRODUCTION OF VALOCTOCOGENE ROXAPARVOVEC-RVOX INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 11)

• 47 XW033G5 (INTRODUCTION OF SARILUMAB INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 5)

• 48 XW033G6 (INTRODUCTION OF REGN-COV2 MONOCLONAL ANTIBODY INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 49 XW033G7 (INTRODUCTION OF ALLOGENEIC ENGINEERED CHIMERIC ANTIGEN RECEPTOR T-CELL IMMUNOTHERAPY INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 50 XW033H5 (INTRODUCTION OF TOCILIZUMAB INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 5)

• 51 XW033H6 (INTRODUCTION OF OTHER NEW TECHNOLOGY MONOCLONAL ANTIBODY INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 52 XW033H7 (INTRODUCTION OF AXICABTAGENE CILOLEUCEL IMMUNOTHERAPY INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 53 XW033J7 (INTRODUCTION OF TISAGENLECLEUCEL IMMUNOTHERAPY INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 54 XW033K5 (INTRODUCTION OF FOSFOMYCIN ANTI-INFECTIVE INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 5)

• 55 XW033K7 (INTRODUCTION OF IDECABTAGENE VICLEUCEL IMMUNOTHERAPY INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 56 XW033K9 (INTRODUCTION OF SULBACTAM-DURLOBACTAM INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 9)

• 57 XW033L6 (INTRODUCTION OF CD24FC IMMUNOMODULATOR INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 58 XW033L7 (INTRODUCTION OF LIFILEUCEL IMMUNOTHERAPY INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 59 XW033M7 (INTRODUCTION OF BREXUCABTAGENE AUTOLEUCEL IMMUNOTHERAPY INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 60 XW033MA (INTRODUCTION OF EMAPALUMAB-LZSG ANTI-IFNY MONOCLONAL ANTIBODY INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 10)

• 61 XW033N5 (INTRODUCTION OF MEROPENEM-VABORBACTAM ANTI-INFECTIVE INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 5)

• 62 XW033N7 (INTRODUCTION OF LISOCABTAGENE MARALEUCEL IMMUNOTHERAPY INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 63 XW033NA (INTRODUCTION OF TARLATAMAB-DLLE ANTINEOPLASTIC INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 10)

• 64 XW033P9 (INTRODUCTION OF GLOFITAMAB ANTINEOPLASTIC INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 9)

• 65 XW033PB (INTRODUCTION OF AZTREONAM-AVIBACTAM ANTI-INFECTIVE INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 11)

• 66 XW033Q5 (INTRODUCTION OF TAGRAXOFUSP-ERZS ANTINEOPLASTIC INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 5)

• 67 XW033Q9 (INTRODUCTION OF POSOLEUCEL INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 9)

• 68 XW033QB (INTRODUCTION OF ILOPROST INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 11)

• 69 XW033R9 (INTRODUCTION OF REZAFUNGIN INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 9)

• 70 XW033RB (INTRODUCTION OF LETETRESGENE AUTOLEUCEL INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 11)

• 71 XW033S5 (INTRODUCTION OF IOBENGUANE I-131 ANTINEOPLASTIC INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 5)

• 72 XW033U5 (INTRODUCTION OF IMIPENEM-CILASTATIN-RELEBACTAM ANTI-INFECTIVE INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 5)

• 73 XW033W5 (INTRODUCTION OF CAPLACIZUMAB INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 5)

• 74 XW033WB (INTRODUCTION OF FOSFOMYCIN ANTI-INFECTIVE INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 11)